Respiratory Inhalers Market - Global Outlook and Forecast 2020-2025
RESPIRATORY INHALERS MARKET SIZE TO REACH USD 5 BILLION BY 2025, GROWING AT A CAGR OF 9% DURING THE FORECAST PERIOD
RESPIRATORY INHALERS MARKET SIZE TO REACH USD 5 BILLION BY 2025, GROWING AT A CAGR OF 9% DURING THE FORECAST PERIOD
This report includes market data points, ranging from trend
analyses to market estimates & forecasts that you can customize
GLOBAL RESPIRATORY INHALERS MARKET REPORT SCOPE
| REPORT ATTRIBUTE | DETAILS |
|---|---|
| MARKET SIZE (REVENUE) | USD 5 BILLION (2025) |
| CAGR | 9% (2020-2025) |
| Base Year | 2019 |
| Historic Year | 2018 |
| Forecast Year | 2020-2025 |
| Market Segments | Product (Metered Dosage and Dry Powder Inhaler), Patient (Adults and Pediatric), Distribution Channels (Hospital Pharmacies, Retail, and Online) |
| Geographic Analysis | North America, Europe, APAC, Latin America, and Middle East & Africa |
| Countries Covered | US, Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, Australia, India, Brazil, Mexico, Argentina, South Africa, Saudi Arabia, and Turkey |
INDUSTRY INSIGHTS
The global respiratory inhalers market size will reach USD 5 billion by 2025, growing at a CAGR of 9% during the forecast period. The market is one of the steadily growing segments in the global medical devices market. The steady growth can be attributed to the growing prevalence of asthma, COPD, and cystic fibrosis and the outbreak of the COVID-19 pandemic. The prevalence of COPD and other respiratory disorders has increased at a significant rate over the last few years across the globe. According to the WHO, COPD is expected to emerge as the third leading cause of death across the world by 2025. The increasing incidence of respiratory diseases and the growing demand for treatment options for respiratory disorders are fueling the market growth of therapeutic respiratory care devices. Further, the presence of established infrastructure in several countries of North America, Europe, and APAC, coupled with the availability of well-developed technologies that allow early implementation of advanced inhalation technologies, increases the demand for inhalers. Favorable government initiatives in emerging economies toward improvising standard healthcare infrastructure and increased focus on healthcare expenditure are also aiding to focus on offering high-quality healthcare services.
SNIPPETS
- The metered dosage inhalers segment is likely to register an incremental growth of over $1 billion by 2025 as MDIs combine the practical benefits of size, portability, convenience, and unobtrusiveness.
- The adult segment is expected to grow at the highest CAGR of over 10% during the period 2019–2025. The growth is on account of the high prevalence of COPD and other respiratory disorders.
- The online segment is observed to register growth at the highest CAGR of over 10% from 2019–2025. The growth is because of the increasing popularity of e-commerce channels in the healthcare sector.
- The APAC region is expected to touch revenue of close to $1.4 billion by 2025. The growth in the region is driven mainly by increased affordability and the presence of a large patient population.
- The respiratory inhalers market in India is expected to grow significantly due to the presence of high asthma and COPD population.
GLOBAL RESPIRATORY INHALERS MARKET SEGMENTATION
This research report includes a detailed segmentation by
- Products
- Patient
- Distribution Channel
- Geography
INSIGHTS BY PRODUCT
The metered dosage inhalers segment is expected to over 2.5 billion by 2025 due to the outbreak of COVID-19, which has led to the increased usage of inhalers among the patients. Pressurized metered dosage inhalers (pMDIs) and dry-powder inhalers (DPIs) are commonly used among end-users. pMDIs are mostly used among developing and underdeveloped countries due to their low price and easy availability in pharmacies. DPI, breath-actuated inhalers, and soft mist inhalers will gain popularity in developed countries such as the US, the UK, and Germany as the treatment in the countries are covered under insurance and reimbursement policies. Developed countries are the matured market, where most advanced versions of smart inhalers are used among people. MDIs are considered as the first line of treatment for major respiratory disorders such as COPD and Asthma. However, a major challenge faced by the segment is the lack of awareness among patients and healthcare providers regarding the correct usage of MDIs.
In 2019, the DPI segment accounted for the share of 46% of the global respiratory inhalers market. The increased efficiency of drug usage is the major driving force for the growth of DPIs. Drug deposition in the lung was twice that of pMDI, which suggests a low dosage of the drug with reduced side-effects helps to achieve the same degree of asthma control. The majority of DPIs have the dose counter, which allows detecting the number of dosages remaining. These devices are user-friendly and convenient; hence they are preferred by patients over MDIs.
INSIGHTS BY PATIENT
The respiratory inhalers market is segmented into pediatric and adults age groups. In. 2019, the adult segment accounted for the share of 68%, and the pediatric population constituted a share of 32% in the respiratory inhalers market. The adult population is widely exposed to several environmental risk factors such as air and workplace pollutions and the consumption of tobacco. This contributes to the high share of the adult population in the market. While the prevalence of asthma is increasing in several countries, multiple factors are affecting the incidence of asthma in the adult population. With the eruption of the COVID-19 pandemic, the number of adults infected is higher than pediatric and neonates populations. Therefore, the demand for inhalers has gone drastically up across the globe due to the spread of the virus.
Managing asthma in pediatrics is not as adults. Pediatric patients are overly sensitive and require a high level of care and comfort and convenient device usage. MDIs, along with spacers, are widely used to treat children suffering from respiratory disorders. Corticosteroids and bronchodilator therapies are routinely delivered by pMDI and the spacer system for children under the age of five years. The prevalence of asthma is higher in urban areas than in rural areas. The incidence of asthma is higher in high-income countries than low- and middle-income ones.
INSIGHTS BY DISTRIBUTION CHANNEL
The hospital pharmacy segment accounted for a share of 47%. Hospitals are the first point of contact for the evaluation and treatment of respiratory diseases such as asthma and COPD. As the number of hospitals has grown over the period, the count of hospital pharmacies has also increased. In the middle- and low-income countries, several smaller clinics, nursing homes have tie-ups with hospital pharmacies to refer patients to purchase branded medical devices for usage.
In 2019, the retail distribution channel segment constituted a share of 43% of the global respiratory inhalers market. Retail pharmacies are picking up pace in the healthcare industry and developing countries such as India, China, Mexico, and other countries. Retail stores have been a proven model for consumers to buy products and services. The retail market holds immense potential because most countries are underpenetrated. In developing countries, the demand for retail pharmacy stores is increasing drastically. Major retail pharmacies in India include Noble plus pharmacy, Apollo pharmacy, Wellness forever pharmacy, Med plus health services, and other pharmacies. Hence, with the increase in the global disease burden in the population, the retail pharmacy sector is expected to observe surge. Although the online segment is expected to increase its reach during the forecast period, the segment constituted only a 10% market share in 2019.
INSIGHTS BY GEOGRAPHY
North America has dominated the global inhalers market, and dominance is mainly due to the increase in the prevalence of several respiratory diseases. The US has been the earliest adopters of the latest inhaler technology to reduce the rate of COPD. In North America, both the US and Canada experienced a large-scale adoption of these devices over the last decade. The rise in pollution rates, along with the growing number of cases of respiratory troubles, is one of the major reasons that boosts the overall demand in the region. Besides, since the outbreak of the COVID pandemic, the need for inhalers has grown significantly in ICUs and emergency rooms. A large population on a medical ventilator are supported with inhalers for increased effectiveness of the medicine. Although the market is expected to grow at a slower rate than other regions, there is a surge in demand for inhalers in the region, especially in the US owing to the COVID-19 pandemic. The country will witness growth as the national health spending is projected to grow at an average annual rate of over 5% during the period 2019–2028, reaching $6.2 trillion by 2028.
INSIGHTS BY VENDORS
The global respiratory inhalers market share is fragmented with the presence of several global, regional, and local vendors offering a wide range of products. GSK, Novartis, BOEHRINGER INGELHEIM, Cipla, and AstraZeneca are the key players dominating the global market. Although large vendors dominate the market, they are witnessing heavy competition from regional and local companies from India, China, Italy, and Germany. Many regional vendors are also offering cost-effective products in Europe, APAC, and the Middle East & Africa regions.
The global respiratory inhalers market research report includes in-depth coverage of the industry analysis with revenue and forecast insights for the following segments:
By Product
- Metered Dosage Inhaler
- Dry Powder Inhaler
By Patient
- Adults
- Pediatric
By Distribution Channel
- Hospital Pharmacies
- Retail
- Online
By Geography
- North America
- US
- Canada
- Europe
- UK
- Germany
- France
- Italy
- Spain
- APAC
- China
- Japan
- South Korea
- Australia
- India
- Latin America
- Brazil
- Mexico
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- Turkey
SNAPSHOT
The respiratory inhalers market by revenue is expected to grow at a CAGR of over 9% during the period 2019–2025.
The following factors are likely to contribute to the growth of the respiratory inhalers market during the forecast period:
- Increase in Usage of Smart Inhaler
- Introduction of Soft Mist Inhalers
- Increase in Target Population
- Surge in Inhalers Usage due to COVID-19
Base Year: 2019
Forecast Year: 2020–2025
The study considers the present scenario of the respiratory inhalers market and its market dynamics for the period 2019−2025. It covers a detailed overview of several market growth enablers, restraints, and trends. The report offers both the demand and supply aspect of the market. It profiles and examines leading companies and other prominent ones operating in the market.
Prominent Vendors
- GlaxoSmithKline
- Business Overview
- Product Offerings
- Key Strengths
- Key Strategies
- Key Opportunities
- Novartis
- Boehringer Ingelheim
- Cipla
- AstraZeneca
Other Prominent Vendors
- Propeller Health
- Business Overview
- Product Offerings
- Beximco Pharmaceuticals (Beximco Pharma)
- H&T Presspart
- Cohero Health
- CHIESI Farmaceutici
- Mundipharma
- 3M
- HELTMAN Medikal
- Adherium
- Luckys Pharma
- Amiko Digital Health
- Teva Pharmaceutical Industries
- Findair Sp.z.o.o
- Vectura Group
Segmentation by Products
- Metered Dosage Inhaler
- Dry Powder Inhaler
Segmentation by Patient
- Adults
- Pediatric
Segmentation by Distribution Channel
- Hospital Pharmacies
- Retail
- Online
Segmentation by Geography
- North America
- US
- Canada
- Europe
- UK
- Germany
- France
- Italy
- Spain
- APAC
- China
- Japan
- South Korea
- Australia
- India
- Latin America
- Brazil
- Mexico
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- Turkey
Frequently Asked Questions
What are the respiratory inhalers market size and growth rate during the forecast period?
What are the factors impacting the growth of the respiratory inhalers market share?
How is the growth of the hospital pharmacies segment influencing the respiratory inhalers market growth?
Who are the leading vendors in the respiratory inhalers market, and what are their market shares?
Which distribution channel will witness the highest growth in selling the respiratory inhalers?
List Of Exhibits
Exhibit 1 Market Segmentation of Global Respiratory Inhalers Market
Exhibit 2 Market Size Calculation Approach 2019
Exhibit 3 Evolution of Respiratory Inhalers
Exhibit 4 Respiratory Inhalers Family Tree
Exhibit 5 Decision Tree For COVID-19 Patients
Exhibit 6 Mortality Rate of COVID-19 by Age Group
Exhibit 7 Impact of Increase in Usage of Smart Inhaler
Exhibit 8 Impact of Introduction of Soft Mist Inhalers
Exhibit 9 Comparison of Drug Delivery Efficiency in pMDI & SMI - Fractionation of Dosage From pMDI & SMIs
Exhibit 10 Impact of Surge in Inhalers Usage due to COVID-19
Exhibit 11 COVID-19 Cases Comparison – Regional wise by WHO
Exhibit 12 Impact of Respiratory Inhalers Designed to the Specific Drugs
Exhibit 13 Impact of Technological Advances in Inhalers
Exhibit 14 Impact of Increase in Target Population
Exhibit 15 Population Aged 60 Years & Above: Segmented by Region 2017 & 2050
Exhibit 16 Prevalence of COPD in Various Countries
Exhibit 17 Impact of Lack of Awareness and Errors in Usage of Inhalers
Exhibit 18 Common Errors in pMDI Usage from Multiple Studies
Exhibit 19 Common Errors in DPI Usage from Multiple Studies
Exhibit 20 Critical Errors During the Usage of MDI
Exhibit 21 Critical Errors Occur During the Usage of DPI
Exhibit 22 Impact of Challenges in Inhaler Usage
Exhibit 23 Factors Impacting Patient Onboarding & Adherence
Exhibit 24 Impact of Global Warming Impacting the Inhaler Usage
Exhibit 25 Global Respiratory Inhalers Market 2019–2025 ($ million)
Exhibit 26 Global Respiratory Inhalers Market by Product: 2019 & 2025 Percentage Share Comparison
Exhibit 27 Global Respiratory Inhalers Market by Patient: 2019 & 2025 (% share comparison)
Exhibit 28 Global Respiratory Inhalers Market by Distribution Channel: 2019 & 2025 (% share comparison)
Exhibit 29 Global Respiratory Inhalers Market by Geography: 2019 & 2025 (% share comparison)
Exhibit 30 Five Forces Analysis 2019
Exhibit 31 Incremental Growth by Product 2019 & 2025
Exhibit 32 Global Respiratory Inhalers Market by Product
Exhibit 33 Global Market by Product: Incremental Growth
Exhibit 34 Global Market by Product: Absolute Growth
Exhibit 35 COVID-19 Impact on Product Segment
Exhibit 36 Respiratory Inhalers Market Product – Metered Dosage Inhaler: Incremental Growth & Absolute Growth Comparison
Exhibit 37 Global Metered Dosage Inhaler Market 2019–2025 ($ million)
Exhibit 38 Incremental Growth by Segment 2019 & 2025
Exhibit 39 Global Pressurized Metered Dosage Market: Incremental Growth & Absolute Growth Comparison
Exhibit 40 Global Pressurized Metered Dosage Market 2019–2025 ($ million)
Exhibit 41 Global Breath Actuated MDIs Market: Incremental Growth & Absolute Growth Comparison
Exhibit 42 Global Breath Actuated Metered Dosage Inhalers Market 2019–2025 ($ million)
Exhibit 43 Global Dry Powder Market: Incremental Growth & Absolute Growth Comparison
Exhibit 44 Global Dry Powdered Market 2019–2025 ($ million)
Exhibit 45 Global SMI Market: Incremental Growth & Absolute Growth Comparison
Exhibit 46 Global Soft Mist Inhaler Market 2019–2025 ($ million)
Exhibit 47 Incremental Growth by Patient Group 2019 & 2025
Exhibit 48 Global Respiratory Inhalers Market by Patient Group
Exhibit 49 Global Market by Patient Group: Incremental Growth
Exhibit 50 Global Market by Patient Group: Absolute Growth
Exhibit 51 Global Market by Patient Group: COVID-19 Impact
Exhibit 52 Socio-Economic Cost of Childhood Asthma
Exhibit 53 Global Market by Pediatric Patient Group: Incremental Growth & Absolute Growth Comparison
Exhibit 54 Global Market by Pediatric Patients 2019–2025 ($ million)
Exhibit 55 Global Market by Adults Patient Group: Incremental Growth & Absolute Growth Comparison
Exhibit 56 Global Market by Adult Patient Group 2019–2025 ($ million)
Exhibit 57 Incremental Growth by Segment 2019 & 2025
Exhibit 58 Respiratory Inhalers Classification Based on Distribution Channel
Exhibit 59 Global Respiratory Inhalers Market by Product: Incremental Growth
Exhibit 60 Global Market by Product: Absolute Growth
Exhibit 61 COVID-19 Impact on Product Segment
Exhibit 62 Respiratory Inhalers Market Distribution Channel – Hospital Pharmacy: Incremental Growth & Absolute Growth Comparison
Exhibit 63 Global by Hospital Pharmacies 2019–2025 ($ million)
Exhibit 64 Respiratory Inhalers Market Distribution Channel – Retail Pharmacy: Incremental Growth & Absolute Growth Comparison
Exhibit 65 Global Market by Retail Pharmacies 2019–2025 ($ million)
Exhibit 66 Market Distribution Channel – Online: Incremental Growth & Absolute Growth Comparison
Exhibit 67 Global Market by Online Distribution Channel 2019–2025 ($ million)
Exhibit 68 Incremental Growth by Geography 2019 & 2025
Exhibit 69 Global Respiratory Inhalers Market by Geography
Exhibit 70 Global Market by Geography: Key Countries 2019 ($ million)
Exhibit 71 Global Market by Geography: Incremental Growth
Exhibit 72 Global Market by Geography: Absolute Growth
Exhibit 73 COVID-19 Impact on Geography Segment
Exhibit 74 Respiratory Inhalers Market in North America: Key Countries ($ million)
Exhibit 75 Market in North America: Incremental Growth & Absolute Growth Comparison
Exhibit 76 Market in North America 2019–2025 ($ million)
Exhibit 77 Incremental Growth in North America 2019 & 2025
Exhibit 78 Asthma Prevalence in US 2018
Exhibit 79 Market in US 2019–2025 ($ million)
Exhibit 80 Market in Canada 2019–2025 ($ million)
Exhibit 81 Hospitalization Rate of Asthma Patients in European Countries
Exhibit 82 Respiratory Inhalers Market in Europe: Key Countries ($ million)
Exhibit 83 Market in Europe: Incremental Growth & Absolute Growth Comparison
Exhibit 84 Market in Europe 2019–2025 ($ million)
Exhibit 85 Incremental Growth in North America 2019 & 2025
Exhibit 86 Market in UK 2019–2025 ($ million)
Exhibit 87 Market in Germany 2019–2025 ($ million)
Exhibit 88 Market in France 2019–2025 ($ million)
Exhibit 89 Market in Spain 2019–2025 ($ million)
Exhibit 90 Global Market in Italy 2019–2025 ($ million)
Exhibit 91 Respiratory Inhalers Market in APAC: Key Countries ($ million)
Exhibit 92 Market in APAC: Incremental Growth & Absolute Growth Comparison
Exhibit 93 Market in APAC 2019–2025 ($ million)
Exhibit 94 Incremental Growth in APAC 2019 & 2025
Exhibit 95 Market in China 2019–2025 ($ million)
Exhibit 96 Market in Japan 2019–2025 ($ million)
Exhibit 97 Market in India 2019–2025 ($ million)
Exhibit 98 Market in South Korea 2019–2025 ($ million)
Exhibit 99 Market in Australia 2019–2025 ($ million)
Exhibit 100 Respiratory Inhalers Market in Latin America: Key Countries ($ million)
Exhibit 101 Market in Latin America: Incremental Growth & Absolute Growth Comparison
Exhibit 102 Market in Latin America 2019–2025 ($ million)
Exhibit 103 Incremental Growth in Latin America 2019 & 2025
Exhibit 104 Market in Brazil 2019–2025 ($ million)
Exhibit 105 Market in Mexico 2019–2025 ($ million)
Exhibit 106 Market in Argentina 2019–2025 ($ million)
Exhibit 107 Respiratory Inhalers Market in Middle East & Africa: Key Countries ($ million)
Exhibit 108 Market in Middle East & Africa: Incremental Growth & Absolute Growth Comparison
Exhibit 109 Market in Middle East & Africa 2019–2025 ($ million)
Exhibit 110 Incremental Growth in Middle East & Africa 2019 & 2025
Exhibit 111 Market in Turkey 2019–2025 ($ million)
Exhibit 112 Market in South Africa 2019–2025 ($ million)
Exhibit 113 Market in Saudi Arabia 2019–2025 ($ million)
Exhibit 114 GlaxoSmithKline Revenue 2017-2019 ($ million)
Exhibit 115 GlaxoSmithKline: Research & Development Expenditure ($ million)
Exhibit 116 Novartis Revenue 2017-2019 ($ million)
Exhibit 117 Novartis: Research & Development Expenditure ($ million)
Exhibit 118 Boehringer Ingelheim Revenue 2018 & 2019 ($ billion)
Exhibit 119 Boehringer Ingelheim: Research & Development Expenditure ($ million)
Exhibit 120 Boehringer Ingelheim Revenue by Business Segments 2019
Exhibit 121 Cipla Revenue 2017-2019 ($ billion)
Exhibit 122 Cipla: Percentage Share of R&D Expenditure in Revenue
Exhibit 123 AstraZeneca Revenue 2017-2019 ($ million)
Exhibit 124 AstraZeneca: Research & Development Expenditure ($ million)
Exhibit 125 AstraZeneca Revenue by Segments ($ million)
List Of Tables
Table 1 Key Caveats
Table 2 Currency Conversion 2013−2019
Table 3 Smart Inhalers Offered in the Market
Table 4 Prescribed Drugs with Inhalers Devices
Table 5 Commonly Used DPIs Produced by Key Players
Table 6 Limitations Associated with Various Respiratory Inhalers
Table 7 Advantages and Disadvantages of Metered Dosage Inhaler
Table 8 Advantages and Disadvantages of Dry Powder Inhalers
Table 9 Advantages and Disadvantages of SMIs
Table 10 Guidelines – Choice of Inhalers for Children Younger than five years
Table 11 Overview of Distribution Channels in Key Markets
Table 12 Comparison of Online vs. Conventional Pharmacy
Table 13 Global Respiratory Inhalers Market: Vendors Ranking
Table 14 GlaxoSmithKline: Major Product Offerings
Table 15 Novartis: Major Product Offerings
Table 16 Boehringer Ingelheim: Major Product Offerings
Table 17 Cipla: Major Product Offerings
Table 18 AstraZeneca: Major Product Offerings
Table 19 Propeller Health: Major Product Offerings
Table 20 Beximo Pharmaceuticals: Major Product Offerings
Table 21 H&T Presspart: Major Product Offerings
Table 22 Cohero Health: Major Product Offerings
Table 23 CHIESI Farmaceutici: Major Product Offerings
Table 24 Mundipharma: Major Product Offerings
Table 25 3M: Major Product Offerings
Table 26 HELTMAN Medikal: Major Product Offerings
Table 27 Adherium: Major Product Offerings
Table 28 Luckys Pharma: Major Product Offerings
Table 29 Amiko Digital Health: Major Product Offerings
Table 30 Teva Pharmaceutical Industries: Major Product Offerings
Table 31 Findair Sp.z.o.o.: Major Product Offerings
Table 32 Vectura Group: Major Product Offerings
Table 33 Global Respiratory Inhalers Market by Geography 2019−2025 ($ million)
Table 34 Global Market by Geography 2019−2025 (%)
Table 35 Global Respiratory Inhalers Market by Patients 2019−2025 ($ million)
Table 36 Global Market by Patients 2019−2025 (%)
Table 37 Global Respiratory Inhalers Market by Product 2019−2025 ($ million)
Table 38 Global Market by Product 2019−2025 (%)
Table 39 Global Respiratory Inhalers Market by Distribution Channel 2019−2025 ($ million)
Table 40 Global Market by Distribution Channel 2019−2025 (%)
1 Research Methodology
2 Research Objectives
3 Research Process
4 Scope & Coverage
4.1 Market Definition
4.1.1 Inclusions
4.1.2 Exclusions
4.2 Base Year
4.3 Scope of The Study
4.3.1 Market Segmentation by Product
4.3.2 Market Segmentation by Patient
4.3.3 Market Segmentation by Distribution Channel
4.3.4 Market Segmentation by Geography
5 Report Assumptions & Caveats
5.1 Key Caveats
5.2 Currency Conversion
5.3 Market Derivation
6 Market at a Glance
7 Introduction
7.1 Overview
7.2 Impact Of Covid-19
7.2.1 Overview
8 Market Opportunities & Trends
8.1 Increase In Usage Of Smart Inhaler
8.2 Introduction Of Soft Mist Inhalers
8.3 Surge In Inhalers Usage Due To Covid-19
9 Market Growth Enablers
9.1 Respiratory Inhalers Designed To The Specific Drugs
9.2 Technological Advances In Inhalers
9.3 Increase In Target Population
10 Market Restraints
10.1 Lack Of Awareness And Errors In Usage Of Inhalers
10.2 Challenges In Inhalers Usage
10.3 Global Warming Impacting The Use Of Inhalers
11 Market Landscape
11.1 Market Overview
11.2 Market Size & Forecast
11.3 Five Forces Analysis
11.3.1 Threat Of New Entrants
11.3.2 Bargaining Power Of Buyers
11.3.3 Bargaining Power Of Suppliers
11.3.4 Threat Of Substitutes
11.3.5 Competitive Rivalry
12 Respiratory Inhalers Market by Product
12.1 Snapshot & Growth Engine
12.2 Overview
12.3 Metered Dosage Inhalers
12.3.1 Overview
12.3.2 Size & Forecast
12.3.3 Snapshot & Growth Engine
12.3.4 Pressurized Metered Dosage Inhalers
12.3.5 Overview
12.3.6 Size & Forecast
12.3.7 Breath Actuated Mdis
12.3.8 Overview
12.3.9 Size & Forecast
12.4 Dry Powder Inhalers
12.4.1 Overview
12.4.2 Size & Forecast
12.5 Soft Mist Inhalers
12.5.1 Overview
12.5.2 Size & Forecast
13 Respiratory Inhalers Market by Patient Group
13.1 Market Snapshot & Growth Engine
13.2 Overview
13.3 Pediatric Patients
13.3.1 Overview
13.3.2 Size & Forecast
13.4 Adults
13.4.1 Overview
13.4.2 Size & Forecast
14 Respiratory Inhalers Market by Distribution Channel
14.1 Snapshot & Growth Engine
14.2 Overview
14.3 Hospital Pharmacies
14.3.1 Overview
14.3.2 Size & Forecast
14.4 Retail Pharmacies
14.4.1 Overview
14.4.2 Size & Forecast
14.5 Online
14.5.1 Overview
14.5.2 Size & Forecast
15 Respiratory Inhalers Market by Geography
15.1 Snapshot & Growth Engine
15.2 Geographic Overview
16 North America
16.1 Overview
16.2 Size & Forecast
16.3 Key Countries
16.3.1 US: Respiratory Inhalers Market Size & Forecast
16.3.2 Canada: Size & Forecast
17 Europe
17.1 Overview
17.2 Size & Forecast
17.3 Key Countries
17.3.1 UK: Respiratory Inhalers Market Size & Forecast
17.3.2 Germany: Size & Forecast
17.3.3 France: Respiratory Inhalers Market Size & Forecast
17.3.4 Spain: Size & Forecast
17.3.5 Italy: Respiratory Inhalers Market Size & Forecast
18 APAC
18.1 Overview
18.2 Size & Forecast
18.3 Key Countries
18.3.1 China: Respiratory Inhalers Market Size & Forecast
18.3.2 Japan: Size & Forecast
18.3.3 India: Respiratory Inhalers Market Size & Forecast
18.3.4 South Korea: Market Size & Forecast
18.3.5 Australia: Respiratory Inhalers Market Size & Forecast
19 Latin America
19.1 Overview
19.2 Size & Forecast
19.3 Key Countries
19.3.1 Brazil: Respiratory Inhalers Market Size & Forecast
19.3.2 Mexico: Size & Forecast
19.3.3 Argentina: Respiratory Inhalers Market Size & Forecast
20 Middle East & Africa
20.1 Overview
20.2 Size & Forecast
20.3 Key Countries
20.3.1 Turkey: Respiratory Inhalers Market Size & Forecast
20.3.2 South Africa: Size & Forecast
20.3.3 Saudi Arabia: Respiratory Inhalers Market Size & Forecast
21 Competitive Landscape
21.1 Competition Overview
21.2 Market Share Analysis
21.2.1 Cipla
21.2.2 GSK
21.2.3 Novartis
21.2.4 Boehringer Ingelheim
21.2.5 Astrazeneca
22 Key Company Profiles
22.1 Glaxosmithkline
22.1.1 Business Overview
22.1.2 Product Offerings
22.1.3 Key Strategies
22.1.4 Key Strengths
22.1.5 Key Opportunities
22.2 Novartis
22.2.1 Business Overview
22.2.2 Product Offerings
22.2.3 Key Strategies
22.2.4 Key Strengths
22.2.5 Key Opportunities
22.3 Boehringer Ingelheim
22.3.1 Business Overview
22.3.2 Product Offerings
22.3.3 Key Strategies
22.3.4 Key Strengths
22.3.5 Key Opportunities
22.4 Cipla
22.4.1 Business Overview
22.4.2 Product Offerings
22.4.3 Key Strategies
22.4.4 Key Strengths
22.4.5 Key Opportunities
22.5 AstraZeneca
22.5.1 Business Overview
22.5.2 Product Offerings
22.5.3 Key Strategies
22.5.4 Key Strengths
22.5.5 Key Opportunities
23 Other Prominent Vendors
23.1 Propeller Health
23.1.1 Business Overview
23.1.2 Product Offerings
23.2 Beximco Pharmaceuticals
23.2.1 Business Overview
23.2.2 Product Offerings
23.3 H&T Presspart
23.3.1 Business Overview
23.3.2 Product Offerings
23.4 Cohero Health
23.4.1 Business Overview
23.4.2 Product Offerings
23.5 CHIESI Farmaceutici
23.5.1 Business Overview
23.5.2 Product Offerings
23.6 Mundipharma
23.6.1 Business Overview
23.6.2 Product Offerings
23.7 3M
23.7.1 Business Overview
23.7.2 Product Offerings
23.8 HELTMAN Medikal
23.8.1 Business Overview
23.8.2 Product Offerings
23.9 Adherium
23.9.1 Business Overview
23.9.2 Product Offerings
23.10 Luckys Pharma
23.10.1 Business Overview
23.10.2 Product Offerings
23.11 Amiko Digital Health
23.11.1 Business Overview
23.11.2 Product Offerings
23.12 Teva Pharmaceutical Industries
23.12.1 Business Overview
23.12.2 Product Offerings
23.13 Findair Sp. z o. o.
23.13.1 Business Overview
23.13.2 Product Offerings
23.14 Vectura Group
23.14.1 Business Overview
23.14.2 Product Offerings
24 Report Summary
24.1 Key Takeaways
24.2 Strategic Recommendations
25 Quantitative Summary
25.1 By Geography
25.2 By Patients
25.3 By Product
25.4 By Distribution Channel
26 Appendix
26.1 Abbreviations
Select a license type that suits your business needs
Single User Licence
- Report accessible by one user only
- Free 10% or 3 days of customization
- Free post-sale service assistance
- Continuous support through email
5 User Licence
- Report accessible by 5 users within the organization
- Free 15% or 4.5 days of customization
- Continuous support through email and telephone
- Free analyst hour
- Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
Corporate Licence
- Free Datasheet worth $1500
- Report accessible by the entire organization
- Free 20% or 6 days of customization
- Free post-sale service assistance
- Continuous support through email and telephone
- Direct access to lead analysts
- Free analyst hour
- Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
Datasheet Licence
- Report accessible by 1 user only
- Free 15% or 32 hours of customization
- Free post-sale service assistance
- Direct access to lead analysts
Frequently Asked Questions
What are the respiratory inhalers market size and growth rate during the forecast period?
What are the factors impacting the growth of the respiratory inhalers market share?
How is the growth of the hospital pharmacies segment influencing the respiratory inhalers market growth?
Who are the leading vendors in the respiratory inhalers market, and what are their market shares?
Which distribution channel will witness the highest growth in selling the respiratory inhalers?
Other RELATED Reports
Blood Glucose Monitoring Devices Market - Global Outlook and Forecast 2019-2024
Published : March 2019
